Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Vector Pharma.

    Client Virtual Booth

    VECTOR PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vector Pharma
    saudiarabiapng-1555324364png-1605701218 Flag
    Country
    Country
    U.A.E
    Address
    Address
    Building A3, Dubai Silicon Oasis - Dubai
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vectorpharma.me/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vector-pharma
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncopeptides, Vector partner to distribute Oncopeptides’ Pepaxti in MENA region to treat multiple myeloma

    Details:

    Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for the treatment of patients with multiple myeloma.


    Lead Product(s): Melphalan Flufenamide,Dexamethasone

    Therapeutic Area: Oncology Product Name: Pepaxti

    Highest Development Status: ApprovedProduct Type: Peptide

    Recipient: Oncopeptides

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 30, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

    Details:

    Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.


    Lead Product(s): Melphalan Flufenamide,Dexamethasone

    Therapeutic Area: Oncology Product Name: Pepaxti

    Highest Development Status: ApprovedProduct Type: Peptide

    Recipient: Oncopeptides

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration March 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatid...

    Details:

    Vector will employ its sales and marketing expertise to distribute both Skytrofa (lonapegsomatropin-tcgd) and Yorvipath in the GCC countries for pediatric growth hormone deficiency in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.


    Lead Product(s): Lonapegsomatropin

    Therapeutic Area: Endocrinology Product Name: Skytrofa

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Ascendis Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement January 08, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East

    Details:

    Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.


    Lead Product(s): Ixabepilone,Capecitabine

    Therapeutic Area: Oncology Product Name: Ixempra

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: R-Pharm

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    fermion-oy-2024-05-13

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search